Tesamorelin vs CJC-1295

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification that protects it from enzymatic degradation. By acting on GHRH receptors in the anterior pituitary, tesamorelin stimulates endogenous GH release with downstream IGF-1 elevation. It has been extensively studied in metabolic research contexts involving visceral adiposity. CJC-1295 is a synthetic GHRH analog available in two forms: without DAC (Drug Affinity Complex) and with DAC. The non-DAC version has a half-life of approximately 30 minutes and produces pulsatile GH release similar to natural GHRH. The DAC version covalently binds to circulating albumin, extending the half-life to roughly 8 days and producing sustained GH elevation rather than pulsatile patterns.

Tesamorelin

Structure Full 44-aa GHRH + hexenoic acid
Half-Life ~30 minutes
GH Pattern Pulsatile (mimics natural GHRH)
Research Focus Visceral adipose tissue, body composition
Receptor Target GHRH receptor (pituitary)
Administration Frequency Daily in study models

CJC-1295

Structure 29-aa GHRH analog (with/without DAC)
Half-Life ~30 min (no DAC) / ~8 days (with DAC)
GH Pattern Pulsatile (no DAC) / Sustained (DAC)
Research Focus GH axis modulation, sustained release studies
Receptor Target GHRH receptor (pituitary)
Administration Frequency Daily (no DAC) / Weekly (DAC)

The Verdict

Tesamorelin and CJC-1295 are both GHRH analogs that stimulate endogenous growth hormone release, but they differ in stability and GH release patterns. Tesamorelin uses the full GHRH sequence with hexenoic acid modification for enzymatic stability, producing natural pulsatile GH release. CJC-1295 with DAC extends the half-life dramatically through albumin binding, allowing less frequent administration but producing sustained rather than pulsatile GH elevation. The choice depends on whether the research question requires natural pulsatile patterns or sustained GH availability.

Tesamorelin vs CJC-1295 — FAQ

What is DAC in CJC-1295?
DAC stands for Drug Affinity Complex, a maleimide modification that covalently binds the peptide to circulating albumin. This dramatically extends the half-life from minutes to days, allowing less frequent dosing but producing sustained rather than pulsatile GH release.
Why pulsatile vs sustained GH release?
Natural GHRH produces pulsatile GH release, which is preferred in research models that aim to mimic physiological patterns. Sustained release (CJC-1295 with DAC) is studied when constant GH elevation is the experimental variable.
Are these the same as exogenous growth hormone?
No. Both stimulate endogenous GH release through the pituitary GHRH receptor, preserving the feedback mechanisms and pulsatile patterns of natural GH secretion. Direct GH administration bypasses these regulatory systems.
What is the regulatory status?
Both are sold as research-use-only compounds for in-vitro and preclinical study models.

References

Primary sources for key clinical and regulatory claims on this page.

  1. Tesamorelin, a human growth hormone releasing factor analogue — PubMed / Expert Opin Investig Drugs . Comprehensive review of tesamorelin pharmacology as a GHRH analog in metabolic research.
  2. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 — PubMed / J Clin Endocrinol Metab . Primary source for CJC-1295 sustained GH and IGF-1 elevation through albumin binding.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Peptides CategoryGrowth-Hormone Hub
Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now